Integrated Investment Consultants’s Regeneron Pharmaceuticals REGN Stock Holding History

Integrated Investment Consultants’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-756	Closed	-$425K	–	325
2025 Q3	$425K	Buy	756 +72	+11%	+$40.7K	0.07%	169
2025 Q2	$359K	Sell	684 -210	-23%	-$117K	0.07%	196
2025 Q1	$567K	Buy	894 +285	+47%	+$196K	0.11%	136
2024 Q4	$434K	Buy	609 +39	+7%	+$32.7K	0.09%	177
2024 Q3	$599K	Buy	570 +262	+85%	+$292K	0.13%	122
2024 Q2	$296K	Hold	308	–	–	0.08%	201
2024 Q1	$296K	Buy	+308	New	+$293K	0.08%	201
2018 Q2	–	Sell	-22	Closed	-$8K	–	575
2018 Q1	$8K	Buy	+22	New	+$7.65K	﹤0.01%	670
2017 Q3	$1K	Buy	+3	New	+$1.43K	﹤0.01%	631

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Integrated Investment Consultants's REGN Position: Q4 2025 in Review

Integrated Investment Consultants sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 756 shares — an estimated $425K sold.

Integrated Investment Consultants first reported a position in REGN in Q3 2017 and held it in 9 quarters. The position peaked at $599K in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Integrated Investment Consultants reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Integrated Investment Consultants sold 756 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $425K.
Integrated Investment Consultants first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 9 quarters.
Integrated Investment Consultants's Regeneron Pharmaceuticals position peaked at $599K in Q3 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Integrated Investment Consultants's 13F filing for Q4 2025, filed 5 Feb 2026.